Joel Greenblatt's PFE Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 1.47 M shares of Pfizer Inc. (PFE) worth $37.51 M, representing 0.16% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in PFE, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2018, adding 1.36 M shares. Largest reduction occurred in Q2 2019, reducing 1.06 M shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Pfizer (PFE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pfizer (PFE) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +18,093 | Add 0.00% | 18,092 | $28.02 |
| Q3 2013 | +46,958 | Add 259.55% | 65,050 | $28.73 |
| Q4 2013 | +157,230 | Add 241.71% | 222,280 | $30.63 |
| Q1 2014 | +792,528 | Add 356.54% | 1.01 M | $32.12 |
| Q2 2014 | +726,506 | Add 71.59% | 1.74 M | $29.68 |
| Q3 2014 | -119,222 | Reduce 6.85% | 1.62 M | $29.57 |
| Q4 2014 | -201,144 | Reduce 12.40% | 1.42 M | $31.15 |
| Q1 2015 | +551,840 | Add 38.84% | 1.97 M | $34.79 |
| Q2 2015 | -948,224 | Reduce 48.07% | 1.02 M | $33.53 |
| Q3 2015 | +23,297 | Add 2.27% | 1.05 M | $31.41 |
| Q4 2015 | -1.05 M | Sold Out | 1.05 M | $0.00 |
| Q1 2016 | +1.58 M | New Buy | 1.58 M | $29.64 |
| Q2 2016 | +361,019 | Add 22.89% | 1.94 M | $35.21 |
| Q3 2016 | -779,345 | Reduce 40.21% | 1.16 M | $33.87 |
| Q4 2016 | -399,563 | Reduce 34.48% | 759,374 | $32.48 |
| Q1 2017 | +185,286 | Add 24.40% | 944,660 | $34.21 |
| Q2 2017 | -473,732 | Reduce 50.15% | 470,928 | $33.59 |
| Q3 2017 | -449,111 | Reduce 95.37% | 21,817 | $35.71 |
| Q4 2017 | +28,105 | Add 128.82% | 49,922 | $36.22 |
| Q1 2018 | +1.36 M | Add 2732.64% | 1.41 M | $35.49 |
| Q2 2018 | -140,811 | Reduce 9.96% | 1.27 M | $36.28 |
| Q3 2018 | -819,658 | Reduce 64.37% | 453,641 | $44.07 |
| Q4 2018 | +140,800 | Add 31.04% | 594,441 | $43.65 |
| Q1 2019 | +882,130 | Add 148.40% | 1.48 M | $42.47 |
| Q2 2019 | -1.06 M | Reduce 72.11% | 411,783 | $43.32 |
| Q3 2019 | -403,692 | Reduce 98.04% | 8,091 | $35.97 |
| Q4 2019 | +805,654 | Add 9957.41% | 813,745 | $39.18 |
| Q1 2020 | +196,870 | Add 24.19% | 1.01 M | $32.64 |
| Q2 2020 | -79,258 | Reduce 7.84% | 931,357 | $32.70 |
| Q3 2020 | -421,369 | Reduce 45.24% | 509,988 | $36.70 |
| Q4 2020 | +12,180 | Add 2.39% | 522,168 | $36.81 |
| Q1 2021 | -33,529 | Reduce 6.42% | 488,639 | $36.23 |
| Q2 2021 | -11,409 | Reduce 2.33% | 477,230 | $39.16 |
| Q3 2021 | +54,946 | Add 11.51% | 532,176 | $43.01 |
| Q4 2021 | -158,691 | Reduce 29.82% | 373,485 | $59.05 |
| Q1 2022 | -82,192 | Reduce 22.01% | 291,293 | $51.77 |
| Q2 2022 | +29,725 | Add 10.20% | 321,018 | $52.43 |
| Q3 2022 | +6,819 | Add 2.12% | 327,837 | $43.76 |
| Q4 2022 | -59,149 | Reduce 18.04% | 268,688 | $51.24 |
| Q1 2023 | +184,535 | Add 68.68% | 453,223 | $40.80 |
| Q2 2023 | +78,965 | Add 17.42% | 532,188 | $36.68 |
| Q3 2023 | -9,267 | Reduce 1.74% | 522,921 | $33.17 |
| Q4 2023 | -462,443 | Reduce 88.43% | 60,478 | $28.79 |
| Q1 2024 | -26,788 | Reduce 44.29% | 33,690 | $27.75 |
| Q2 2024 | -8,214 | Reduce 24.38% | 25,476 | $27.98 |
| Q3 2024 | +7,070 | Add 27.75% | 32,546 | $28.94 |
| Q4 2024 | +108,494 | Add 333.36% | 141,040 | $26.53 |
| Q1 2025 | +287,925 | Add 204.14% | 428,965 | $25.34 |
| Q2 2025 | +475,105 | Add 110.76% | 904,070 | $24.24 |
| Q3 2025 | +568,016 | Add 62.83% | 1.47 M | $25.48 |
Joel Greenblatt's Pfizer Investment FAQs
Joel Greenblatt first purchased Pfizer Inc. (PFE) in Q2 2013, acquiring 18,092 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Pfizer Inc. (PFE) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to Pfizer Inc. (PFE) was in Q1 2016, adding 1,577,263 shares worth $46.75 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 1,472,086 shares of Pfizer Inc. (PFE), valued at approximately $37.51 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Pfizer Inc. (PFE) represents approximately 0.16% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in Pfizer Inc. (PFE) was 1,972,788 shares, as reported at the end of Q1 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.